Results 1 to 10 of about 94,605 (281)

ASOG: AntiSense Oligonucleotide Generator [PDF]

Computational and Structural Biotechnology Journal
Antisense oligonucleotides (ASOs) are used in both fundamental research and clinical applications to modulate gene expression by targeting the RNA transcript of specific genes.
Jonah Kimi, Patricia Korczak, Brune Vialet, Eric Roubin, Philippe Barthélémy, Sébastien Campagne, Florian Malard   +6 more
doaj   +2 more sources

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol [PDF]

Molecular Therapy: Nucleic Acids, 2015
We developed an efficient system for delivering short interfering RNA (siRNA) to the liver by using α-tocopherol conjugation. The α-tocopherol–conjugated siRNA was effective and safe for RNA interference–mediated gene silencing in vivo. In contrast, when
Tomoko Nishina, Junna Numata, Kazutaka Nishina, Kie Yoshida-Tanaka, Keiko Nitta, Wenying Piao, Rintaro Iwata, Shingo Ito, Hiroya Kuwahara, Takeshi Wada, Hidehiro Mizusawa, Takanori Yokota   +11 more
doaj   +4 more sources

Potential antisense oligonucleotide targeting LINC00673 on proliferation and apoptosis in tongue squamous cell carcinoma [PDF]

Journal of Taibah University Medical Sciences
الملخص: أهداف البحث: تزداد معدلات الإصابة بسرطان اللسان، المعروف بطبيعته العدوانية، سنويًّا في إندونيسيا وعلى مستوى العالم. ويرتبط أحد العوامل الجزيئية المرتبطة بسرطان اللسان البشري بارتفاع التعبير عن الحمض النووي الريبوزي الطويل غير المشفِّر (LINC٠٠٦٧٣)
Kadek Gede Putra Wibawa, DDS, Supriatno, PhD, Juni Handajani, PhD   +2 more
doaj   +2 more sources

Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry [PDF]

Molecular Therapy: Nucleic Acids, 2019
Eluforsen (previously known as QR-010) is a 33-mer 2′-O-methyl modified phosphorothioate antisense oligonucleotide targeting the F508del mutation in the gene encoding CFTR protein of cystic fibrosis patients.
Jaeah Kim, Babak Basiri, Chopie Hassan, Carine Punt, Erik van der Hage, Cathaline den Besten, Michael G. Bartlett   +6 more
doaj   +2 more sources

Antisense oligonucleotide targeting nicotinamide N-methyltransferase exhibits antitumor effects [PDF]

Molecular Therapy: Nucleic Acids
Nicotinamide N-methyltransferase (NNMT) is one of the methyltransferase family genes. It consumes S-adenosyl-l-methionine (SAM), which is required for DNA methylation and histone methylation for epigenetic regulation, to produce 1-methylnicotinamide from
Tomoaki Hara, Sikun Meng, Yuuya Kasahara, Takashi Osawa, Daisuke Motooka, Hiromichi Sato, Yasuko Arao, Yoshiko Saito, Kana Inoue, Yumiko Hamano, Yuichiro Doki, Hidetoshi Eguchi, Satoshi Obika, Hideshi Ishii   +13 more
doaj   +2 more sources

Antisense Oligonucleotide Therapy for Calmodulinopathy. [PDF]

Circulation
BACKGROUND: Calmodulinopathies are rare inherited arrhythmia syndromes caused by dominant heterozygous variants in CALM1 , CALM2 , or CALM3 , which each encode the identical CaM (calmodulin) protein. We hypothesized that antisense
Bortolin RH, Nawar F, Park C, Trembley MA, Prondzynski M, Sweat ME, Wang P, Chen J, Lu F, Liou C, Berkson P, Keating EM, Yoshinaga D, Pavlaki N, Samenuk T, Cavazzoni CB, Sage PT, Ma Q, Whitehill RD, Abrams DJ, Carreon CK, Putra J, Alexandrescu S, Guo S, Tsai WC, Rubart M, Kubli DA, Mullick AE, Bezzerides VJ, Pu WT.   +29 more
europepmc   +3 more sources

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis [PDF]

Annals of Clinical and Translational Neurology
Antisense oligonucleotides, which are used to silence target genes, are gaining attention as a novel drug discovery modality for proteinopathies. However, while clinical trials for neurodegenerative diseases like amyotrophic lateral sclerosis have been ...
Daisuke Ito, Kensuke Okada
doaj   +2 more sources

An LNA gapmer antisense oligonucleotide inhibitor of human NNMT. [PDF]

Mol Ther Nucleic Acids
Chen S, Poudel BH, Veedu RN.
europepmc   +2 more sources

Glycogen for Smyd3-antisense oligonucleotide delivery and enhanced liver cancer gene therapy. [PDF]

RSC Adv
Bai N, Huang Y, Shen J, Peng Y, Zhang H, Hou D.   +5 more
europepmc   +3 more sources

Antisense oligonucleotides [PDF]

Neurology Genetics, 2019
There are few disease-modifying therapeutics for neurodegenerative diseases, but successes on the development of antisense oligonucleotide (ASO) therapeutics for spinal muscular atrophy and Duchenne muscular dystrophy predict a robust future for ASOs in medicine.
Scoles, Daniel R., Minikel, Eric V., Pulst, Stefan M.   +2 more
openaire   +3 more sources